Immunoglobulin A1 complex (IgA1 complex)

Immunoglobulin A1 complex (“IgA1 complex” or “human IgA1 complex”) refers to an aggregate form of the human antibody subclass IgA1, often in complex with antigens or other serum proteins such as human serum albumin (HSA) or forming immune complexes. IgA1 is a predominant subclass of immunoglobulin, highly present in serum and mucosal tissues, characterized by a hinge region with O-linked glycans and a structure that includes heavy and light chains arranged into Fab and Fc regions[1][2][3][5]. When complexed (e.g., as immune complexes), IgA1 acts as part of the immune response and can mediate antigen clearance via interaction with Fcα receptors on immune cells, activating effector functions such as phagocytosis and respiratory burst[5][7]. However, deposition of these complexes in tissues, particularly in glomeruli of the kidney, is implicated in the pathogenesis of diseases like IgA nephropathy (IgAN)[5]. Aberrant glycosylation of the IgA1 hinge region is frequently associated with disease states, making these complexes a biomarker and therapeutic consideration in conditions involving immune complex deposition[5]. **Note:** - “IgA1 complex” is not a single molecular entity but designates aggregated or complexed states of IgA1; thus, it is not considered a canonical drug target in the manner of a cell surface receptor or enzyme[6][7]. - Nonetheless, its role in disease pathogenesis makes it highly relevant in translational research, biomarker development, and as an indirect therapeutic target (by modulating their formation, clearance, or deposition)[5][6][7].

Other names

IgA1 immune complexIgA1-containing immune complexhuman IgA1-HSA complex

Not applicable (as this is not a classic molecular target for direct drug action)